BRD9 and myelodysplastic syndrome: In myelodysplasias (MDS) and uveal melanomas (UVM) with mutant SF3B1, BRD9 is reported to undergo alternative splicing leading to inclusion of a poison exon causing mRNA degradation, also implicating BRD9 as a potential oncogene in those tumors [33].